Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tae-Bong Kang

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Immunity|July 19, 2018
Programmed Cell Death in Immune Defense: Knowledge and PresumptionsDavid Wallach, Tae-Bong Kang
Cells|September 13, 2019
The Molecular Links between Cell Death and InflammasomeKwang-Ho Lee, Tae-Bong Kang
Nature Reviews. Immunology|December 17, 2013
Concepts of tissue injury and cell death in inflammation: a historical perspectiveDavid Wallach, Tae-Bong Kang, Andrew Kovalenko
Trends in Immunology|September 6, 2011
'Necrosome'-induced inflammation: must cells die for it?David Wallach, Andrew Kovalenko, Tae-Bong Kang
Expert Opinion on Therapeutic Patents|August 30, 2016
Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patentsSpandana Rajendra Kopalli, Tae-Bong Kang, Sushruta Koppula
Methods in Molecular Biology (Clifton, N.J.)|February 25, 2022
In Vitro and In Vivo Model for Sepsis Through Non-canonical NLRP3 Inflammasome ActivationXiao Sun, Tae-Bong Kang, Kwang-Ho Lee
Cytokine & Growth Factor Reviews|January 14, 2014
The in vivo significance of necroptosis: lessons from exploration of caspase-8 functionDavid Wallach, Tae-Bong Kang, Seung-Hoon Yang, et al.
Science (New York, N.Y.)|April 2, 2016
Programmed necrosis in inflammation: Toward identification of the effector moleculesDavid Wallach, Tae-Bong Kang, Christopher P Dillon, et al.
Recent Patents on Anti-Cancer Drug Discovery|October 28, 2017
NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent PatentsSpandana R Kopalli, Tae-Bong Kang, Kwang-Ho Lee, et al.
Biomolecules|January 5, 2021
Molecular Targeting of VEGF with a Suramin Fragment-DOCA Conjugate by Mimicking the Action of Low Molecular Weight HeparinsJooho Park, Tae-Bong Kang, Ji-Hong Lim, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Immunity|July 19, 2018
Programmed Cell Death in Immune Defense: Knowledge and PresumptionsDavid Wallach, Tae-Bong Kang
Cells|September 13, 2019
The Molecular Links between Cell Death and InflammasomeKwang-Ho Lee, Tae-Bong Kang
Nature Reviews. Immunology|December 17, 2013
Concepts of tissue injury and cell death in inflammation: a historical perspectiveDavid Wallach, Tae-Bong Kang, Andrew Kovalenko
Trends in Immunology|September 6, 2011
'Necrosome'-induced inflammation: must cells die for it?David Wallach, Andrew Kovalenko, Tae-Bong Kang
Expert Opinion on Therapeutic Patents|August 30, 2016
Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patentsSpandana Rajendra Kopalli, Tae-Bong Kang, Sushruta Koppula
Methods in Molecular Biology (Clifton, N.J.)|February 25, 2022
In Vitro and In Vivo Model for Sepsis Through Non-canonical NLRP3 Inflammasome ActivationXiao Sun, Tae-Bong Kang, Kwang-Ho Lee
Cytokine & Growth Factor Reviews|January 14, 2014
The in vivo significance of necroptosis: lessons from exploration of caspase-8 functionDavid Wallach, Tae-Bong Kang, Seung-Hoon Yang, et al.
Science (New York, N.Y.)|April 2, 2016
Programmed necrosis in inflammation: Toward identification of the effector moleculesDavid Wallach, Tae-Bong Kang, Christopher P Dillon, et al.
Recent Patents on Anti-Cancer Drug Discovery|October 28, 2017
NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent PatentsSpandana R Kopalli, Tae-Bong Kang, Kwang-Ho Lee, et al.
Biomolecules|January 5, 2021
Molecular Targeting of VEGF with a Suramin Fragment-DOCA Conjugate by Mimicking the Action of Low Molecular Weight HeparinsJooho Park, Tae-Bong Kang, Ji-Hong Lim, et al.
Pageof 8